A Phase 3 clinical trial has shown that LYN-005—a once-weekly oral capsule formulation of risperidone—achieves comparable bioavailability and symptom control to daily dosing in patients with schizophrenia or schizoaffective disorder. Conducted at five sites across the U.S. and enrolling 83 participants, the study was stopped early following positive interim results. Designed to release risperidone gradually in the stomach, LYN-005 may offer a middle ground between daily oral medications and long-acting injectable options, potentially improving patient adherence.

Throughout the trial, mean scores on the Positive and Negative Syndrome Scale (PANSS) remained stable in the mid-50s, reflecting mild symptom severity and effective disease control across all LYN-005 dose groups. Adverse events were generally mild and primarily gastrointestinal in nature. The findings underscore the critical role of adherence in managing schizophrenia and support LYN-005 as a promising alternative for patients who prefer oral treatment. The study was sponsored by Lyndra Therapeutics.

From Medscape